Abstract
Although COVID-19 continued to dominate headlines in 2021, biotech firms didn’t stop pushing their therapies forward this year. Psychedelic drugs, stem cell therapies, and multiple gene-editing technologies showed promise for treating mental illnesses, chronic diseases, and genetic conditions. The data behind these new approaches are preliminary at best. In some instances, the therapies were tested in just a few people. And it’s too soon to know how safe or effective these therapies will be in larger populations. But if any of them prove successful, the implications could be huge. These are just a few of the emerging approaches that C&EN will be watching in the years to come. Psychedelic drugs show promise for mental illness A growing number of academic groups and biotech companies are betting that psychedelic drugs, still illegal in most of the US, could help people with serious mental illnesses . Initial trials are testing these drugs
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
